Publication:
Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.

dc.contributor.authorRodrigo, T
dc.contributor.authorCasals, M
dc.contributor.authorCaminero, J A
dc.contributor.authorGarcía-García, J M
dc.contributor.authorJiménez-Fuentes, M A
dc.contributor.authorMedina, J F
dc.contributor.authorMillet, J P
dc.contributor.authorRuiz-Manzano, J
dc.contributor.authorCaylá, J
dc.contributor.authorWorking Group of the Integrated Programme of Tuberculosis Research
dc.date.accessioned2023-01-25T08:35:02Z
dc.date.available2023-01-25T08:35:02Z
dc.date.issued2016-08-03
dc.description.abstractTo determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8-283.4); being retired (HR = 2.4;CI:1.1-5.1); having visited the emergency department (HR = 3.1;CI:1.2-7.7); HIV infection (HR = 3.4;CI:1.6-7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2-3.3) or non-standard treatments (HR = 2.68;CI:1.36-5.25); comprehension difficulties (HR = 2.8;CI:1.3-6.1); and smear-positive sputum (HR = 2.3-CI:1.0-4.8). There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs.
dc.identifier.doi10.1371/journal.pone.0159925
dc.identifier.essn1932-6203
dc.identifier.pmcPMC4972388
dc.identifier.pmid27487189
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/pdf
dc.identifier.unpaywallURLhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0159925&type=printable
dc.identifier.urihttp://hdl.handle.net/10668/10331
dc.issue.number8
dc.journal.titlePloS one
dc.journal.titleabbreviationPLoS One
dc.language.isoen
dc.organizationIBIS
dc.page.numbere0159925
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntitubercular Agents
dc.subject.meshCoinfection
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRisk Factors
dc.subject.meshSurvival Analysis
dc.subject.meshTuberculosis
dc.subject.meshYoung Adult
dc.titleFactors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC4972388.pdf
Size:
638.63 KB
Format:
Adobe Portable Document Format